N-acetylcysteine for contrast nephropathy: More clinical science is required [5]

Archives of Internal Medicine

Volumn 166, Issue 15, 2006, Pages 1668-1669

  Eddleston, Michael ^a   Goddard, Jane ^b   Bateman, Nick ^b  

^a ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; CONTRAST MEDIUM; CREATININE; CYSTEINE; PARACETAMOL;

ANTIOXIDANT ACTIVITY; CLINICAL RESEARCH; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DRUG INDUCED DISEASE; DRUG MECHANISM; EVIDENCE BASED MEDICINE; FIRST PASS EFFECT; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY BLOOD FLOW; KIDNEY DISEASE; KIDNEY INJURY; LETTER; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RADIOGRAPHY; RENAL ARTERY; TREATMENT OUTCOME; VASOCONSTRICTION;

ACETYLCYSTEINE; CONTRAST MEDIA; HUMANS; KIDNEY; KIDNEY FAILURE, ACUTE;

EID: 33747175355     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinte.166.15.1668-b     Document Type: Letter

References (5)

1. Bagshaw SM, McAlister FA, Manns BJ, Ghali WA. Acetylcysteine in the prevention of contrast-induced nephropathy: a case study of the pitfalls in the evolution of evidence. Arch Intern Med. 2006;166:161-166.
2. Shalansky SJ, Vu T, Pate GE, Levin A, Humphries KH, Webb JG. N-acetylcysteine for prevention of radiographic contrast material-induced nephropathy: is the intravenous route best? Pharmacotherapy. 2005;25:1095-1103.
3. Stacul F. Reducing the risks for contrast-induced nephropathy. Cardiovasc Intervent Radiol. 2005;28(suppl 2):S12-S18.
4. Manjunath G, Sarnak MJ, Levey AS. Estimating the glomerular filtration rate: dos and don'ts for assessing kidney function. Postgrad Med. 2001;110:55-62.
5. Hoffmann U, Fischereder M, Kruger B, Drobnik W, Kramer BK. The value of N-acetylcysteine in the prevention of radiocontrast agent-induced nephropathy seems questionable. J Am Soc Nephrol. 2004;15:407-410.